PCSK9 and familial hyperaldosteronism: Inhibitors of PCSK9 are a recent development for the management of FH, and have been recommended to be used in very high-risk patients who fail to achieve their LDL-C targets while receiving maximally tolerated statin treatment with or without ezetimibe; when there is intolerance to the use of statins, PCSK9 inhibitors can be used as monotherapy or in combination with ezetimibe [5,14].